Gerd Binnig Awarded 2016 Kavli Prize

MUNICH–(BUSINESS WIRE)– The Kavli Prize Committee has announced the award of the Kavli Prize in
Nanoscience to Gerd Binnig, Christoph Gerber, and Calvin Quate “for the
invention and realization of atomic force microscopy, a breakthrough in
measurement technology and nanosculpting that continues to have a
transformative impact on nanoscience and technology.” The Kavli Prizes
recognize scientists for pioneering advances of the understanding of the
universe at its biggest, smallest, and most complex scales. Laureates
are chosen by committees whose members are recommended by six of the
world’s most renowned science societies and academies.

The breakthrough of the atomic force microscope (AFM) combined the
principles of scanning tunneling microscopy (STM) with the invention of
the stylus profilometer to achieve atomic resolution. STM was a
breakthrough invented by Binnig together with Heinrich Rohrer earlier
for which they both received the Nobel
Prize for Physics in 1986.

Commented Binnig, “I have always been interested in how to make the
invisible, visible. It is gratifying to see that these inventions have
had wide impact by not only kicking-off the field of nanotechnology, but
also in biology with the AFM enabling the measurements of dynamic
processes of individual molecules like proteins and of interaction
forces within and between those biomolecules.”

Binnig is the founder and CTO of Definiens AG. The past few years he has
been working to advance the field of cancer therapy and immuno-oncology
using the Cognition Network Technology®, invented by the Definiens team
he leads, to mine tissue data and discover new signatures to stratify
patients and match them to therapies. For more information on the Kavli
Prize, please see www.kavliprize.org.
For more information on Definiens, please see www.definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for
biomarker and companion diagnostics development and commercialization.
Definiens’ technology empowers smarter tissue-based diagnostics by
leveraging quantitative tissue readouts and other big data sources. By
enabling the development of powerful and precise assays for patient
stratification and clinical trial enrollment, Definiens aims to
dramatically improve patient outcomes. Definiens’ Tissue Phenomics
approach was awarded the 2013 Frost and Sullivan Company of the Year
Award for Global Tissue Diagnostics and Pathology Imaging. For more
information, please visit: www.definiens.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160608006387/en/